<- Go Home
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Market Cap
$12.0B
Volume
358.4K
Cash and Equivalents
$227.0M
EBITDA
-$312.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$1.1B
Profit Margin
93.07%
52 Week High
$615.00
52 Week Low
$265.00
Dividend
N/A
Price / Book Value
22.00
Price / Earnings
-38.02
Price / Tangible Book Value
22.30
Enterprise Value
$11.5B
Enterprise Value / EBITDA
-37.11
Operating Income
-$313.5M
Return on Equity
49.35%
Return on Assets
-17.62
Cash and Short Term Investments
$812.8M
Debt
$347.3M
Equity
$543.5M
Revenue
$1.1B
Unlevered FCF
-$141.3M
Sector
Biotechnology
Category
N/A